Vycor Medical Inc. (VYCO) 1.4600 $VYCO
Vycor Medical Releases Financial Results for the Three Months Ended March 31st, 2015
ACCESSWIRE - Fri May 15, 2:45PM CDT
BOCA RATON, FL / ACCESSWIRE / May 15, 2015 / Vycor Medical, Inc. ("Vycor"
(OTCQB: VYCO), today announced financial results for the three months ended March 31, 2015.
Allowance of Key Patent Focused on VBAS Integration with Neuro-navigation
ACCESSWIRE - Thu Apr 09, 7:30AM CDT
BOCA RATON, FL / ACCESSWIRE / April 9, 2015 / Vycor Medical, Inc. ("Vycor" (OTCQB:VYCO), a provider of innovative and superior surgical and therapeutic solutions announced that following on from its recent acquisition of a patent portfolio relating to neuro-navigation the United States Patent and Trademark Office has issued a notice that it allowed one of Vycor's own pending applications directed to novel neuro-navigation systems for neurosurgical access systems.
Vycor Medical Releases Financial Results for the Twelve Months Ended December 31st, 2014
ACCESSWIRE - Tue Mar 31, 7:52AM CDT
Vycor VBAS up 23% compared to 2013; Non-GAAP Net Loss reduced by 7%
Two New Published Clinical Papers on Vycor Medical's VBAS Point to New Procedures, Broader Market Potential, and Improved Safety
ACCESSWIRE - Thu Mar 26, 3:26AM CDT
BOCA RATON, FL / ACCESSWIRE / March 26, 2015 / Vycor Medical, Inc. ("Vycor" (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that two new important peer-reviewed studies have been published utilizing its ViewSite Brain Access System ("VBAS" . The studies appear in the March editions of World Neurosurgery and Neurological Research, and follow on from the study published earlier this month in the prestigious Journal of Neurosurgery which also featured VBAS on its front cover.
Vycor Announces Completion of Software Development of NovaVision's Web Deliverable VRT
ACCESSWIRE - Mon Mar 16, 7:30AM CDT
BOCA RATON, FL / ACCESSWIRE / March 16, 2015 / Vycor Medical, Inc. ("Vycor" (OTCQB:VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced the development completion of its web delivered Vision Restoration Therapy (VRT) therapy. The Company has re-engineered its VRT to enable it for direct-to-patient internet delivery and to streamline a number of business processes related to the delivery and servicing of patients; the therapy itself has remained unchanged. The Company further confirmed that the internet-based program was on track to be commercially launched during the second quarter of 2015 and will replace the Company's current "prototype hardware centric" model. For an overview of NovaVision see NovaVision Video.
Vycor Medical's VBAS Showcased on Cover of Prestigious Journal of Neurosurgery
ACCESSWIRE - Mon Mar 09, 9:14AM CDT
BOCA RATON, FL / ACCESSWIRE / March 9, 2015 / Vycor Medical, Inc. ("Vycor" (OTCQB:VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that its VBAS was selected to be on the cover of the March edition of the prestigious Journal of Neurosurgery (JNS). Founded in 1944, the Journal of Neurosurgery is recognized by neurosurgeons and related medical specialists worldwide for its authoritative and cutting-edge clinical articles, laboratory research papers, case reports, literature reviews, technical notes, book reviews and more. The Journal of Neurosurgeryis cited more often than any other journal dedicated to the field of neurosurgery.
Vycor Medical Adds to Patent Portfolio with Key Focus on VBAS Integration with Neuro-navigation
ACCESSWIRE - Tue Mar 03, 7:02AM CST
BOCA RATON, FL / ACCESSWIRE / March 3, 2015 / Vycor Medical, Inc. ("Vycor" (OTCQB:VYCO), a provider of innovative and superior surgical and therapeutic solutions announced that it had agreed to pay $65,000 to purchase a patent portfolio for its Vycor Medical division. The portfolio comprises two pending United States applications which disclose approaches to integrating surgical navigation systems into optically-transparent neurosurgical obturators. These applications complement and strengthen Vycor's existing portfolio, particularly in relation to its ongoing focus to integrate neuro-navigation systems and methods into the existing ViewSite Brain Access System (VBAS).
Vycor Announces Commercial Launch of NeuroEyeCoach(TM) Professional Physician Edition
ACCESSWIRE - Mon Nov 24, 7:00AM CST
BOCA RATON, FL / ACCESSWIRE / November 24, 2014 / Vycor Medical, Inc. ("Vycor" (OTCQB-VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that its wholly owned subsidiary NovaVision, Inc. had successfully completed the development of and was in the process of commercially launching its NeuroEyeCoach(TM) Professional Physician Edition. The launch of this Edition was the result of demand from physicians who wanted to be able to initiate patients on the NeuroEyeCoach(TM) program in their office or clinic and then have patients continue the program at home, supported by NovaVision staff, while being able to monitor the patient's progress through a dedicated portal access point.
Vycor Medical to Present at the LD Micro Conference on December 3
ACCESSWIRE - Tue Nov 18, 7:00AM CST
BOCA RATON, FL/ ACCESSWIRE / November 18, 2014 / Vycor Medical, Inc. ("Vycor" (OTCQB-VYCO), a provider of innovative and superior surgical and therapeutic solutions, is pleased to announce that Peter Zachariou, Chief Executive Officer and David Cantor, President, will present at the LD MICRO Conference at 9:30 a.m. (PT), Track 3, on Wednesday, December 3, 2014. The conference will be held December 2-4, 2014 at the Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, CA. The Company's group presentation will be available for the public to access at http://wsw.com/webcast/ldmicro7/vyco. This webcast will be archived for 90 days following the live presentation. Vycor Medical management will be available during the day on December 3 for one-on-one meetings. Please contact LD MICRO to schedule a meeting.
Vycor Medical Releases Financial Results for Third Quarter and First Nine Months of 2014
ACCESSWIRE - Wed Nov 12, 12:00PM CST
Vycor VBAS up 41% for first nine months over same period in 2013 Non-GAAP Net Operating Loss reduced by 12%
VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 125.90 (+3.00), ABMD: 68.66 (+1.21), JNJ: 103.42 (+1.12), AMGN: 163.44 (+1.08), EXAS: 24.30 (+1.33), ARAY: 6.11 (-0.05), HOLX: 34.62 (+0.18), PBYI: 181.30 (+4.29)
Leading Neurosurgeon to Present at Vycor's Booth at Congress of Neurological Surgeons in Boston
Marketwired - Thu Oct 16, 7:31AM CDT
Vycor Medical, Inc. ("Vycor" (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, is pleased to announce that Dr. Antonio Bernardo, from the Department of Neurological Surgery at Weill Cornell Medical College, will present and field questions on his recent work on minimally invasive neurosurgical approaches through Vycor Medical's ViewSite(TM) Brain Access System (VBAS) at the 2014 meeting of the Congress of Neurological Surgeons in Boston, Massachusetts. Dr. Bernardo will demonstrate the novel techniques developed in his laboratory that may mitigate the risk of postoperative seizures, aphasia, and venous complications through minimization of brain retraction in the middle fossa approach and other selected skull base procedures while improving cosmetic outcomes. Additionally, by limiting the range of instrument movement and protecting the surrounding tissues from instruments within the working channel, the tubular retractor may reduce inadvertent iatrogenic instrumental injury and thermal injury from the endoscope light or electrocautery.
Vycor Continues to Execute on Its Stated Strategic Goal of Expanding Internationally
Marketwired - Mon Oct 13, 7:01AM CDT
Vycor Medical, Inc. ("Vycor" (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that it had made significant in-roads into a number of key international markets. Most recently it has entered into a distribution agreement with Eurotech, a leading Russian distributor of surgical devices, and secured its first order. In addition to Russia, Vycor has identified and started to work with neurosurgical distributors in the following markets: Brazil, France, South Africa, Sri Lanka and Taiwan. In each of these markets, Vycor has entered into either evaluation or distribution agreements and is now going through local regulatory approvals. Including these countries, Vycor now has international agreements in place for VBAS in Australia, Belgium, Brazil, Canada, China, France, Germany, Greece, Holland, Hong Kong, Italy, Japan, Korea, Russia, South Africa, Spain, Sri Lanka, Sweden, Taiwan and the UK.
Prominent Researchers to Present Minimally Invasive Surgeries Utilizing Vycor Medical's VBAS at Congress of Neurosurgery
Marketwired - Fri Oct 10, 7:30AM CDT
Vycor Medical, Inc. ("Vycor" (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, is pleased to announce that researchers from the Department of Neurological Surgery at Weill Cornell Medical College will present their recent work on minimally invasive neurosurgical approaches through Vycor Medical's ViewSite(TM) Brain Access System (VBAS) at the 15th European Congress of Neurosurgery in Prague. Prof. Antonio Bernardo, Director of the Surgical Innovations Lab for Skull Base and Microneurosurgery at Weill Cornell, will deliver a presentation on minimally invasive supraorbital and middle fossa approaches to intracranial targets on Tuesday, October 14th at 15:30 in Hall E.
Weill Cornell Neurosurgeons to Present Procedures Carried Out Using Vycor's VBAS at International Congress on Minimally Invasive Techniques in Neurosurgery
Marketwire - Thu Sep 04, 7:36AM CDT
Vycor Medical, Inc. ("Vycor" (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that researchers from the Department of Neurological Surgery at Weill Cornell Medical College will present their recent work on minimally invasive neurosurgical approaches using Vycor Medical's ViewSite(TM) patented Brain Access System (VBAS) next week, from September 11 to 13, at the 2nd International Congress on Minimally Invasive Techniques in Neurosurgery in Xian, China. Members of the research team will meet with surgeons before the conference to demonstrate novel techniques that may help diminish the risk of retraction injury while surgically accessing the third ventricle and which may mitigate the risk of post-operative seizures, aphasia, and venous complications through minimization of brain retraction in the middle fossa approach while improving cosmetic outcomes. The team will also provide an in-depth technical demonstration of these techniques to local surgeons.
Vycor Reports 41% Year-to-Date Revenue Growth
Marketwire - Tue Aug 12, 7:31AM CDT
Vycor Medical, Inc. ("Vycor" (OTCQB: VYCO), today announced financial results for the second quarter and first six months of 2014.
New Image Guided VBAS Prototype Work Completed
Marketwire - Thu Aug 07, 7:00AM CDT
Vycor Medical, Inc. ("Vycor" (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that it had successfully completed the development of new prototypes of its patented ViewSite(TM) Brain Access System ("VBAS" device that will be fully compatible with selected image-guided systems. The device has been specifically designed to house the pointer utilized in image-guided systems. The pointer will be firmly held in place in the introducer through a novel approach while the working channel will remain unchanged. The Company will now commence the testing of these devices. Initially the Company plans on manufacturing four new devices targeted at this market, this development being spurred by strong neurosurgeon demand. VBAS is currently approved in over 170 hospitals in the U.S. and more than 6,500 surgeries have been performed worldwide utilizing VBAS.
Vycor Medical Boosts Shareholder Equity by $2.4 million
Marketwire - Tue Aug 05, 7:31AM CDT
Vycor Medical, Inc. ("Vycor" or the "Company" (OTCQB: VYCO), today announces that its largest shareholder, Fountainhead Capital Management Limited ("Fountainhead" , along with certain other related and non-related parties (together, the "Fountainhead Parties" , has agreed to exchange all of its $2,355,587 of debt into an equivalent amount of preferred equity in the company.
Vycor Medical Releases Financial Results for the Three Months Ended March 31st, 2015
ACCESSWIRE - Fri May 15, 2:45PM CDT
BOCA RATON, FL / ACCESSWIRE / May 15, 2015 / Vycor Medical, Inc. ("Vycor"
(OTCQB: VYCO), today announced financial results for the three months ended March 31, 2015. Allowance of Key Patent Focused on VBAS Integration with Neuro-navigation
ACCESSWIRE - Thu Apr 09, 7:30AM CDT
BOCA RATON, FL / ACCESSWIRE / April 9, 2015 / Vycor Medical, Inc. ("Vycor"
(OTCQB:VYCO), a provider of innovative and superior surgical and therapeutic solutions announced that following on from its recent acquisition of a patent portfolio relating to neuro-navigation the United States Patent and Trademark Office has issued a notice that it allowed one of Vycor's own pending applications directed to novel neuro-navigation systems for neurosurgical access systems. Vycor Medical Releases Financial Results for the Twelve Months Ended December 31st, 2014
ACCESSWIRE - Tue Mar 31, 7:52AM CDT
Vycor VBAS up 23% compared to 2013; Non-GAAP Net Loss reduced by 7%
Two New Published Clinical Papers on Vycor Medical's VBAS Point to New Procedures, Broader Market Potential, and Improved Safety
ACCESSWIRE - Thu Mar 26, 3:26AM CDT
BOCA RATON, FL / ACCESSWIRE / March 26, 2015 / Vycor Medical, Inc. ("Vycor"
(OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that two new important peer-reviewed studies have been published utilizing its ViewSite Brain Access System ("VBAS" . The studies appear in the March editions of World Neurosurgery and Neurological Research, and follow on from the study published earlier this month in the prestigious Journal of Neurosurgery which also featured VBAS on its front cover. Vycor Announces Completion of Software Development of NovaVision's Web Deliverable VRT
ACCESSWIRE - Mon Mar 16, 7:30AM CDT
BOCA RATON, FL / ACCESSWIRE / March 16, 2015 / Vycor Medical, Inc. ("Vycor"
(OTCQB:VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced the development completion of its web delivered Vision Restoration Therapy (VRT) therapy. The Company has re-engineered its VRT to enable it for direct-to-patient internet delivery and to streamline a number of business processes related to the delivery and servicing of patients; the therapy itself has remained unchanged. The Company further confirmed that the internet-based program was on track to be commercially launched during the second quarter of 2015 and will replace the Company's current "prototype hardware centric" model. For an overview of NovaVision see NovaVision Video. Vycor Medical's VBAS Showcased on Cover of Prestigious Journal of Neurosurgery
ACCESSWIRE - Mon Mar 09, 9:14AM CDT
BOCA RATON, FL / ACCESSWIRE / March 9, 2015 / Vycor Medical, Inc. ("Vycor"
(OTCQB:VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that its VBAS was selected to be on the cover of the March edition of the prestigious Journal of Neurosurgery (JNS). Founded in 1944, the Journal of Neurosurgery is recognized by neurosurgeons and related medical specialists worldwide for its authoritative and cutting-edge clinical articles, laboratory research papers, case reports, literature reviews, technical notes, book reviews and more. The Journal of Neurosurgeryis cited more often than any other journal dedicated to the field of neurosurgery. Vycor Medical Adds to Patent Portfolio with Key Focus on VBAS Integration with Neuro-navigation
ACCESSWIRE - Tue Mar 03, 7:02AM CST
BOCA RATON, FL / ACCESSWIRE / March 3, 2015 / Vycor Medical, Inc. ("Vycor"
(OTCQB:VYCO), a provider of innovative and superior surgical and therapeutic solutions announced that it had agreed to pay $65,000 to purchase a patent portfolio for its Vycor Medical division. The portfolio comprises two pending United States applications which disclose approaches to integrating surgical navigation systems into optically-transparent neurosurgical obturators. These applications complement and strengthen Vycor's existing portfolio, particularly in relation to its ongoing focus to integrate neuro-navigation systems and methods into the existing ViewSite Brain Access System (VBAS). Vycor Announces Commercial Launch of NeuroEyeCoach(TM) Professional Physician Edition
ACCESSWIRE - Mon Nov 24, 7:00AM CST
BOCA RATON, FL / ACCESSWIRE / November 24, 2014 / Vycor Medical, Inc. ("Vycor"
(OTCQB-VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that its wholly owned subsidiary NovaVision, Inc. had successfully completed the development of and was in the process of commercially launching its NeuroEyeCoach(TM) Professional Physician Edition. The launch of this Edition was the result of demand from physicians who wanted to be able to initiate patients on the NeuroEyeCoach(TM) program in their office or clinic and then have patients continue the program at home, supported by NovaVision staff, while being able to monitor the patient's progress through a dedicated portal access point. Vycor Medical to Present at the LD Micro Conference on December 3
ACCESSWIRE - Tue Nov 18, 7:00AM CST
BOCA RATON, FL/ ACCESSWIRE / November 18, 2014 / Vycor Medical, Inc. ("Vycor"
(OTCQB-VYCO), a provider of innovative and superior surgical and therapeutic solutions, is pleased to announce that Peter Zachariou, Chief Executive Officer and David Cantor, President, will present at the LD MICRO Conference at 9:30 a.m. (PT), Track 3, on Wednesday, December 3, 2014. The conference will be held December 2-4, 2014 at the Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, CA. The Company's group presentation will be available for the public to access at http://wsw.com/webcast/ldmicro7/vyco. This webcast will be archived for 90 days following the live presentation. Vycor Medical management will be available during the day on December 3 for one-on-one meetings. Please contact LD MICRO to schedule a meeting. Vycor Medical Releases Financial Results for Third Quarter and First Nine Months of 2014
ACCESSWIRE - Wed Nov 12, 12:00PM CST
Vycor VBAS up 41% for first nine months over same period in 2013 Non-GAAP Net Operating Loss reduced by 12%
VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 125.90 (+3.00), ABMD: 68.66 (+1.21), JNJ: 103.42 (+1.12), AMGN: 163.44 (+1.08), EXAS: 24.30 (+1.33), ARAY: 6.11 (-0.05), HOLX: 34.62 (+0.18), PBYI: 181.30 (+4.29)
Leading Neurosurgeon to Present at Vycor's Booth at Congress of Neurological Surgeons in Boston
Marketwired - Thu Oct 16, 7:31AM CDT
Vycor Medical, Inc. ("Vycor"
(OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, is pleased to announce that Dr. Antonio Bernardo, from the Department of Neurological Surgery at Weill Cornell Medical College, will present and field questions on his recent work on minimally invasive neurosurgical approaches through Vycor Medical's ViewSite(TM) Brain Access System (VBAS) at the 2014 meeting of the Congress of Neurological Surgeons in Boston, Massachusetts. Dr. Bernardo will demonstrate the novel techniques developed in his laboratory that may mitigate the risk of postoperative seizures, aphasia, and venous complications through minimization of brain retraction in the middle fossa approach and other selected skull base procedures while improving cosmetic outcomes. Additionally, by limiting the range of instrument movement and protecting the surrounding tissues from instruments within the working channel, the tubular retractor may reduce inadvertent iatrogenic instrumental injury and thermal injury from the endoscope light or electrocautery. Vycor Continues to Execute on Its Stated Strategic Goal of Expanding Internationally
Marketwired - Mon Oct 13, 7:01AM CDT
Vycor Medical, Inc. ("Vycor"
(OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that it had made significant in-roads into a number of key international markets. Most recently it has entered into a distribution agreement with Eurotech, a leading Russian distributor of surgical devices, and secured its first order. In addition to Russia, Vycor has identified and started to work with neurosurgical distributors in the following markets: Brazil, France, South Africa, Sri Lanka and Taiwan. In each of these markets, Vycor has entered into either evaluation or distribution agreements and is now going through local regulatory approvals. Including these countries, Vycor now has international agreements in place for VBAS in Australia, Belgium, Brazil, Canada, China, France, Germany, Greece, Holland, Hong Kong, Italy, Japan, Korea, Russia, South Africa, Spain, Sri Lanka, Sweden, Taiwan and the UK. Prominent Researchers to Present Minimally Invasive Surgeries Utilizing Vycor Medical's VBAS at Congress of Neurosurgery
Marketwired - Fri Oct 10, 7:30AM CDT
Vycor Medical, Inc. ("Vycor"
(OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, is pleased to announce that researchers from the Department of Neurological Surgery at Weill Cornell Medical College will present their recent work on minimally invasive neurosurgical approaches through Vycor Medical's ViewSite(TM) Brain Access System (VBAS) at the 15th European Congress of Neurosurgery in Prague. Prof. Antonio Bernardo, Director of the Surgical Innovations Lab for Skull Base and Microneurosurgery at Weill Cornell, will deliver a presentation on minimally invasive supraorbital and middle fossa approaches to intracranial targets on Tuesday, October 14th at 15:30 in Hall E. Weill Cornell Neurosurgeons to Present Procedures Carried Out Using Vycor's VBAS at International Congress on Minimally Invasive Techniques in Neurosurgery
Marketwire - Thu Sep 04, 7:36AM CDT
Vycor Medical, Inc. ("Vycor"
(OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that researchers from the Department of Neurological Surgery at Weill Cornell Medical College will present their recent work on minimally invasive neurosurgical approaches using Vycor Medical's ViewSite(TM) patented Brain Access System (VBAS) next week, from September 11 to 13, at the 2nd International Congress on Minimally Invasive Techniques in Neurosurgery in Xian, China. Members of the research team will meet with surgeons before the conference to demonstrate novel techniques that may help diminish the risk of retraction injury while surgically accessing the third ventricle and which may mitigate the risk of post-operative seizures, aphasia, and venous complications through minimization of brain retraction in the middle fossa approach while improving cosmetic outcomes. The team will also provide an in-depth technical demonstration of these techniques to local surgeons. Vycor Reports 41% Year-to-Date Revenue Growth
Marketwire - Tue Aug 12, 7:31AM CDT
Vycor Medical, Inc. ("Vycor"
(OTCQB: VYCO), today announced financial results for the second quarter and first six months of 2014. New Image Guided VBAS Prototype Work Completed
Marketwire - Thu Aug 07, 7:00AM CDT
Vycor Medical, Inc. ("Vycor"
(OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that it had successfully completed the development of new prototypes of its patented ViewSite(TM) Brain Access System ("VBAS" device that will be fully compatible with selected image-guided systems. The device has been specifically designed to house the pointer utilized in image-guided systems. The pointer will be firmly held in place in the introducer through a novel approach while the working channel will remain unchanged. The Company will now commence the testing of these devices. Initially the Company plans on manufacturing four new devices targeted at this market, this development being spurred by strong neurosurgeon demand. VBAS is currently approved in over 170 hospitals in the U.S. and more than 6,500 surgeries have been performed worldwide utilizing VBAS. Vycor Medical Boosts Shareholder Equity by $2.4 million
Marketwire - Tue Aug 05, 7:31AM CDT
Vycor Medical, Inc. ("Vycor" or the "Company"
(OTCQB: VYCO), today announces that its largest shareholder, Fountainhead Capital Management Limited ("Fountainhead" , along with certain other related and non-related parties (together, the "Fountainhead Parties" , has agreed to exchange all of its $2,355,587 of debt into an equivalent amount of preferred equity in the company. 
